Our Managing Partner Dave Fitzhenry recently sat down with Brian Orelli from BioWorld Insight where he discussed the findings of our second annual Drug Index. In the article titled, “Winners and losers from the FDA approval class of 2014,” Dave provided a comprehensive overview of the commercial success and performance of each individual drug humorously highlighting how Trinity Partners “envisioned it like looking at NFL draft grades.”
A team of experts from Trinity Partners and Janssen have published an article in Dermatology and Therapy. The paper, titled, “Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis,” describes the results of a study to determine dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. The study concluded that comprehensive education regarding treatment attributes may help minimize the influence of subjective biases and facilitate appropriate and patient-centered treatment selection in psoriasis.
The paper was authored by Gordon Lau, Gretchen R. Chiu, Nandini Hadker, Aparna Deshpande, Stephen Fleming, and Nicola Vance, all of Trinity Partners, along with Seina Lee and Steve Fakharzadeh of Janssen Scientific Affairs. At the time of the study, Matthew Alcusky was a postdoctoral fellow with Thomas Jefferson University and Janssen Scientific Affairs.
To view the full text of the article, please visit http://bit.ly/2hJqe9k
Trinity Partners is proud to officially announce the promotion of Krista Perry and John Greenaway to the role of Principal and to Trinity Partners’ Leadership Team. In their new roles, Krista and John will co-lead Trinity Partners’ San Francisco office and consulting team. They will also partner with other Leadership Team members to drive business development and deliver projects to assist west coast biopharmaceutical clients in optimizing their strategic business decisions, commercial planning, and analytics. Further, both Krista and John continue to support the development and training of managers and junior staff.
A graduate of Dartmouth College, Krista Perry joined Trinity Partners in 2006 and has been serving clients as a project manager since 2013. Krista works in the general strategy consulting group and focuses on commercial assessments, prioritizations and launch planning. She has a focus on commercial support for clients focusing on rare diseases, including significant experience working with Trinity’s primary market research group to conduct qualitative and quantitative global research studies with physicians, patients, advocacy groups, payers and other stakeholders in orphan markets.
In addition to her vast experience in rare disease, Krista has broad experience in women’s health. Last year, she led a pro-bono project for the Bill and Melinda Gates Foundation, helping them assess the potential of a collection of maternal vaccines. Krista has been with Trinity Partners for 11 years.
John Greenaway, a graduate of the University of Michigan and Northwestern University’s Kellogg School of Management, joined Trinity Partners in 2010. As part of the strategy consulting team, John supports the consulting and advisory needs for key pharmaceutical and medical device clients and their commercial executives. John provides senior pharmaceutical executives with analytics-based strategic recommendations in forecasting, market opportunity assessments, licensing and acquisition, and product launch planning.
John co-leads for Trinity’s Pricing, Access, Reimbursement, and Contracting (PARC) service, supporting pharmaceutical companies developing market access strategies and implementing pricing, contracting, and patient support programs. In this role, John has spoken and been a panel moderator at several industry conferences. Notably, John has presented Trinity’s published papers “Innovative Contracting Solutions in a Changing Healthcare Landscape” and “Changes to Medical Benefit Reimbursement and Implications for Drug Contracting and Pricing.” Additionally, he has moderated industry panels on “Best Practices to Develop and Implement Effective Pricing and Contracting Strategies.”
“Krista and John are leaders in the Trinity community, contributing to some of the most critical projects in the Strategy Consulting group,” said Dave Fitzhenry, Managing Partner at Trinity Partners. “Both principals truly deserve this recognition, as they are not only experts in what they do, but also genuine team players. As Trinity continues to grow, we are looking forward to seeing how Krista and John evolve in their new roles.”
About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here.
Trinity Partners, a leading global life sciences consulting firm, today announced the findings of its second annual Trinity Drug Index which assessed all novel drugs approved by the FDA in 2014. The index ranks drug performance against three categories: commercial success, therapeutic value and R&D complexity, assigning each drug a score in those three areas as well as an overall composite score.
Top findings of this year’s Trinity Drug Index include:
· Immuno-oncology agent Keytruda was the best performing drug approved in 2014, followed by Harvoni and Opdivo.
· To be successful, mass-market, primary care products had to demonstrate at least moderate therapeutic innovation coupled with substantial marketing power.
· While several orphan drugs achieved high commercial scores, others (mainly, “ultra-orphans”) were not able to reap the success expected based on their therapeutic value.
· Of products acquired during the regulatory review process or after FDA approval (Esbriet, Northera, Dalvance, Sivextro, and Zerbaxa), all but Esbriet underperformed commercially.
· Anti-infective agents did not perform well commercially despite average to above average therapeutic scores.
“Most of the top performers are innovative specialty drugs targeting multiple niche indications with high unmet needs,” said John Corcoran, Founder and President, Trinity Partners. “With increasing competition and tighter payer and regulatory controls, it’s critical that companies prioritize their investment to ensure an optimal return.”
To shed light on why products over- or under-perform commercially relative to their therapeutic value, the index authors included three case studies. These include a look at Keytruda and Opdivo (overperformers), Zerbaxa (underperformer), and Vimizim and Zykadia (underperformers).
“Even with the unique challenges presented by certain markets, success can be achieved in all therapeutic areas,” said Neal Dunn, Partner, Trinity Partners. “The key to executing a winning clinical and commercial strategy is to clearly and effectively demonstrate the value of novel agents.”
To view the full index, click HERE
Trinity Partners, a leading global life sciences consulting firm, today announced the organization has been named a Fastest Growing Firm by Consulting Magazine. The judges recognized Trinity as having one of the highest rates of revenue growth from 2013 to 2016 among consultancies of all sizes and sectors.
“At Trinity, we understand the importance of creating a culture of smart and motivated individuals who are committed to delivering exceptional work for our clients,” said Dave Fitzhenry, managing partner, Trinity Partners. “We hold ourselves to high standards for recruitment, training and growth opportunities. This ultimately leads to strong retention and supports the continued expansion of our business.”
This is the second consecutive year Trinity has been honored as a Fastest Growing Firm by Consulting Magazine. Throughout Trinity’s 20-year history, the company has honored its vision of leading transformation in the life sciences industry. The company is on pace to exceed its aggressive growth plan and increase organic revenue by over 20 percent in 2018.
Consulting Magazine recognized the Company as a mover and shaker of the consulting profession. Trinity, along with other fastest growing firms, was formally honored at the publication’s annual Awards Dinner on November 2 at the Yale Club in New York City.
This Thursday evening, Trinity’s Neal Dunn will be participating on a panel for Life Science Cares to discuss industry career opportunities with students from the Bottom Line program. The event will be held at EY’s Boston offices from 5:30 – 8:00pm. Learn more about Life Science Cares events here: http://bit.ly/2iz0Pzj
MIT Technology Review Associate Editor Emily Mullin spoke with Trinity Partners’ Herman Sanchez about gene therapy pricing, specifically around the correlation between price of drug, and patient population size. Learn more from their conversation here: http://bit.ly/2xlZZfg
Trinity Partners, a leading global life sciences consulting firm, today announced that Dave Fitzhenry, Managing Partner, was named one of Consulting magazine’s Global Leaders in Consulting 2017. The Global Leaders in Consulting award recipients are chosen based upon their impact, initiative and extraordinary influence in their firms, for their clients and over the entire consulting profession.
“We are so proud of Dave for achieving this award. He was one of the firm’s first members and has proven his value and expertise many times over since day one,” said John Corcoran, Founder and President, Trinity Partners. “His insights consistently make a meaningful impact on critical business decisions for his clients and within our firm and his outstanding leadership has been instrumental in our unmatched global client and employee growth.”
Fitzhenry, a graduate of Harvard University, joined Trinity Partners as the firm’s third employee in 1997 and currently serves as its managing partner. He is a sought-after expert in commercial strategy in the biopharmaceutical industry and his experience includes work with global organizations, as well as in-depth knowledge of the critical areas for new product development. Fitzhenry has extensive knowledge in global markets, across a variety of therapeutic areas and with companies of all sizes, ranging from biotech startups to large-cap pharmaceuticals.
Fitzhenry will be recognized at a celebratory gala awards dinner at Le Meridian Piccadilly in London, United Kingdom on Thursday, December 7 and also included in the January 2018 issue of Consulting magazine.
Trinity Partners, a leading global life sciences consulting firm, today announced, at the NORD Rare Disease and Orphan Products Breakthrough Summit in Washington, D.C., a new whitepaper titled ‘Assessing Value in Ultra-Orphan Markets’.
In the last five to 10 years, the concentration on orphan development has exploded. From acquisitions to creation of separate rare disease units, pharma companies of all sizes have an increased focus on the orphan market. Yet, while rare diseases have the attention of the industry and the incentives continue to be strong, finding success in the orphan market is not easy. This new whitepaper outlines the crucial clinical and commercial attributes that drive success for ultra-orphan, non-oncology products.
Key insights include:
- Potential products (to acquire or for portfolio planning) must first be assessed on several different commercial and clinical criteria specific to ultra-orphan markets.
- Success in the ultra-orphan market does not follow one formula. Soliris (Alexion) and KUVAN (BioMarin) are two assets that score high with regard to clinical and commercial opportunity, yet followed very different paths to success.
- The complexities surrounding success in the ultra-orphan market will continue to grow as competition rises alongside increased payer and pricing sensitivity.
“There are more than 7,000 rare diseases with only 500 approved treatments, which is a clear indicator of a large unmet need and opportunity for success in the orphan market space,” said Herman Sanchez, Partner, Trinity Partners, and lead author of the report. “However, being aware that there is a large market opportunity and truly realizing that opportunity are very different things. Our whitepaper outlines key insights and findings based on our deep commercialization experience in the market, providing companies with a proven roadmap to recognize the critical metrics that determine success and the efforts needed to achieve them.”
Trinity Partners, headquartered in Waltham, MA, with additional offices in San Francisco, New York City and Princeton, New Jersey, has extensive experience in orphan and ultra-orphan markets globally including NA, EUMEA, LATAM and APAC. The firm has more than 150 employees and has worked with six of the top 12 global pharmaceutical companies and 12 of the top 20 specialty and biopharmaceutical companies.
“The industry is driving to more targeted therapies, including new and exciting gene therapies, and many of them could become success stories with the right considerations. We’ve worked with many companies in the U.S. and around the globe on their commercialization strategies and are excited to share key learnings in our new whitepaper,” added Neal Dunn, Partner, Trinity Partners and co-author of the whitepaper.
NORD’s Rare Diseases and Orphan Products Breakthrough Summit is the largest and most meaningful multi-stakeholder event of its kind – featuring more than 20 speakers from the FDA, participation from over 80 patient organizations and the Pharma/Biotech industry’s foremost experts in orphan product innovation, investment and commercialization.
To read the full whitepaper and access all key insights, click here.
Several of Trinity’s Waltham employees attended the Disorder: Rare Disease Film Festival on October 3 in Boston. The event, designed to increase awareness, connect patients and lead to new research paths, was an invaluable experience to
learn about the stories of rare disease patients around the world. Employees also enjoyed hearing from filmmakers, researchers, and patient advocates. The day was a valuable glimpse into the challenges faced by many in the rare disease community on a regular
basis and inspires us to continue helping clients address the needs of patients with rare diseases. For more information about the Disorder: Rare Disease Film Festival, please visit: